Research
What a trial has to tell the person in it
Federal regulation lists what a research subject must be told before agreeing, and it names fourteen separate items. One of them is a sentence about the public trial record, written out word for word in the rule.
Two documents that share a word and share nothing else
Consent turns up twice in this market and means two different things.
One is the box at checkout, which forms a contract. A separate article on this site covers what that box actually signs.
The other is research consent, which is not a contract at all. It is a disclosure a federal rule requires before a person may be enrolled in a study.
That rule lists what has to be disclosed. The list is specific, it is public, and it is short enough to read in a few minutes.
It is the fullest statement in federal law of what a person is owed before taking an unproven compound.
Before any of it is offered, a board has to find seven things
Consent is the last step rather than the first. An ethics board reviews the research, and it may approve only where every one of seven findings is satisfied.
The first is that risks to subjects are minimized, by using procedures consistent with sound research design that do not expose people to unnecessary risk.
The second is that risks are reasonable in relation to anticipated benefits and to the importance of the knowledge expected to result.
That second finding carries a limit worth reading. The board is to consider only risks and benefits arising from the research itself.
It is told not to weigh risks and benefits of treatment a person would have received anyway, and not to weigh long-range effects on public policy.
The third finding is that selection of subjects is equitable, with attention to research involving vulnerable groups.
The fourth and fifth are that consent will be sought from each person, and that it will be appropriately documented.
The sixth is that the plan provides for monitoring the data collected to ensure safety, where appropriate.
The seventh is that there are adequate provisions to protect privacy and keep data confidential.
Where subjects are likely to be vulnerable to coercion or undue influence, additional safeguards have to be built into the study.
The eight things that must be disclosed
The rule calls these the basic elements, and every one has to be provided to each subject.
A statement that the study involves research, an explanation of its purposes, the expected duration, a description of the procedures, and identification of any procedure that is experimental.
A description of any reasonably foreseeable risks or discomforts.
A description of any benefits that may reasonably be expected, to the subject or to others.
A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the person.
A statement describing how far confidentiality of identifying records will be maintained, which must note that the agency may inspect those records.
For research involving more than minimal risk, an explanation of whether compensation and medical treatment are available if injury occurs, what they consist of, or where to find out more.
An explanation of whom to contact about the research, about subjects’ rights, and in the event of a research-related injury.
And a statement that participation is voluntary, that refusing carries no penalty or loss of benefits, and that a person may stop at any time on the same terms.
Six more, when they apply
The rule then lists additional elements, to be provided when appropriate, and several of them answer questions the basic list does not.
That the treatment may involve risks which are currently unforeseeable, including risks to an embryo or fetus.
The circumstances under which an investigator may end someone’s participation without regard to their consent.
Any additional costs to the person that may result from taking part.
The consequences of deciding to withdraw, and the procedures for ending participation in an orderly way.
A statement that significant new findings developed during the research, which may bear on a person’s willingness to continue, will be provided to them.
And the approximate number of subjects involved in the study.
That last item is quietly the most useful of the fourteen. A person is told the size of the thing they are joining.
The sentence about the public record, written out in the rule
For a covered trial, the rule goes further than listing topics. It prescribes an exact statement, and it prints it inside the regulation.
The statement tells the subject that a description of the trial will be available on the public registry, as required by law, and it names the address.
Then it continues, word for word: "This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time."
Read the middle sentence again. Federal regulation tells a research subject, in advance, that the public record will hold at most a summary of the results.
That is the ceiling on what a registry entry is, stated by the rule to the person with the most at stake.
It also explains why the statement exists at all. Its stated purpose is to notify the subject that information about their trial has been or will be submitted to the registry.
A companion article on this site sets out what that registry entry contains, box by box.
Documentation, and the version for people who cannot read the form
Consent has to be documented, and the default is a written form approved by the ethics board.
The person, or their legally authorized representative, signs and dates it at the time of consent, and a copy is given to whoever signed.
The form itself may be one of two things, and the second exists for a real situation.
The first is a written document embodying the required elements. It may be read aloud, and the investigator must still allow adequate opportunity to read it before signing.
The second is a short form stating that the elements were presented orally.
That route carries its own machinery. There has to be a witness to the oral presentation, and the board has to approve a written summary of what will be said.
The person signs only the short form. The witness signs both the short form and a copy of the summary, and whoever obtained the consent signs a copy of the summary.
The person receives a copy of the summary as well as a copy of the short form.
A narrow exception to written documentation sits in the ethics board rules, which a neighboring article on this site describes.
What this rule does not do
It does not preempt anything stricter. The rule says its consent requirements are not intended to displace federal, state or local laws requiring more to be disclosed.
It does not touch emergency care. Nothing in the regulations is intended to limit a physician’s authority to provide emergency medical treatment where the law permits it.
And it does not reach a purchase. These are rules for clinical investigations, and a person buying a compound is not enrolled in one.
That boundary is the honest reading, and it cuts in an uncomfortable direction.
The fullest disclosure federal law requires before someone takes an unproven compound applies to research, where nobody is charged for the product.
A separate rule bars a consent from containing language through which a person waives, or appears to waive, their legal rights. A neighboring article on this site carries it.
Set the fourteen elements beside a checkout page and the difference is not a matter of tone. Different documents exist to do different jobs.
Where a reader can see whether any of it happened
None of this is visible on a product page, and one field on a public record touches it.
A covered trial’s registration record carries a review board status, and it must read approved where at least one board approved the trial.
It may also record that such review is not required by law, which is a different answer and a legitimate one.
The record does not carry the consent form, the board’s reasoning, or the summary approved for oral presentation.
So the public trace is thin: a single field saying a board looked, and the fourteen items the rule required someone to say out loud.
That is still more than exists anywhere else in this market, which is the point of knowing it.
Key takeaways
- Research consent is a disclosure required by regulation, not a contract, and it lists fourteen items in total.
- An ethics board must make seven separate findings before approving a study, including that risks are minimized and selection of subjects is equitable.
- The board is told to weigh only risks and benefits arising from the research, not those of treatment a person would have received anyway.
- The basic elements include foreseeable risks, alternative courses of treatment, and whether compensation or treatment exists if injury occurs.
- Additional elements include unforeseeable risks, additional costs, what happens on withdrawal, and the approximate number of subjects.
- For a covered trial the rule prints an exact statement telling the subject the public record will hold at most a summary of the results.
- Consent is documented on a board-approved written form, or on a short form with a witness and a board-approved oral summary.
- None of this reaches a purchase, and the only public trace is the review board status field on a registration record.
Frequently asked questions
What has to be disclosed before someone joins a clinical trial?
Eight basic elements, and six more where they apply. The basic list covers that the study is research, its purposes and duration, the procedures and which of them are experimental. It covers foreseeable risks, expected benefits, and alternative courses of treatment. It covers how confidentiality will be handled, and that the agency may inspect the records. It covers compensation and treatment for injury in more than minimal risk research, and whom to contact. And it covers that participation is voluntary and can stop at any time without penalty.
What are the additional elements for?
They cover situations the basic list does not. Currently unforeseeable risks, including to an embryo or fetus. Circumstances in which an investigator may end participation without regard to consent. Additional costs. The consequences of withdrawing and how to withdraw in an orderly way. A promise that significant new findings bearing on willingness to continue will be passed on. And the approximate number of subjects in the study.
Does a consent form have to mention the public trial registry?
For a covered trial, the rule prescribes the exact statement. It says a description of the trial will be available on the public registry, as required by law. It then continues, word for word, that the site will not include information that can identify the subject. It adds that at most the site will include a summary of the results, and that the subject can search it at any time.
What must an ethics board find before approving a study?
Seven things, all of them. That risks are minimized by sound design. That risks are reasonable against anticipated benefits and the importance of the knowledge expected. That selection of subjects is equitable. That consent will be sought from each person and appropriately documented. That the plan provides for monitoring data to ensure safety where appropriate. And that privacy and confidentiality are adequately protected.
Can consent be given without signing a long document?
Yes, through a short form, and the rule builds in checks. The short form states that the required elements were presented orally. A witness must be present for that presentation, and the board must approve a written summary of what is said. The subject signs only the short form; the witness signs the short form and a copy of the summary, and the person obtaining consent signs a copy of the summary. The subject receives copies of both.
Do these rules apply when someone buys a compound online?
No. They govern clinical investigations, and a purchase is not enrollment in one. That boundary is worth stating plainly rather than implying a violation. The fourteen disclosure elements describe what federal law requires before a person takes an unproven compound inside research, where the product is not being sold to them.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 21 CFR 50.25 — Elements of informed consent, including the basic and additional elements and the prescribed statement about the public trial registry — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 50.27 — Documentation of informed consent, including the written form and the short form with a witness — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 56.111 — Criteria for IRB approval of research, the seven findings a board must make — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 50.3 — Definitions, including minimal risk, human subject and legally authorized representative — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 42 CFR 11.28 — Clinical trial registration information, including the Human Subjects Protection Review Board Status data element — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026